electroCore

electroCore is a publicly traded bioelectronic medicine company headquartered in Basking Ridge, New Jersey, specializing in non-invasive vagus nerve stimulation technology. The company's flagship product, gammaCore, is a handheld, non-invasive device that delivers mild electrical stimulation to the vagus nerve through the skin of the neck. Unlike traditional neurostimulation approaches that require surgical implantation, gammaCore offers a drug-free therapeutic option that patients can self-administer. The device works by modulating the body's inflammatory and neurological pathways via the vagus nerve, which plays a central role in autonomic function and immune response.

electroCore has secured FDA clearance for gammaCore across several indications, including the acute and preventive treatment of cluster headache and the prevention of migraine in adults. The company has built a growing clinical evidence base, with multiple peer-reviewed studies supporting the safety and efficacy of its non-invasive vagus nerve stimulation platform. electroCore has also pursued expanded applications beyond headache disorders, including research into inflammatory conditions such as rheumatoid arthritis and post-COVID symptoms. The company trades publicly on the NASDAQ under the ticker ECOR, and has worked to establish reimbursement pathways and commercial partnerships, including notable supply agreements with the U.S. Department of Defense for servicemember healthcare.

electroCore represents an important proof of concept for the broader bioelectronic medicine field, demonstrating that neuromodulation therapies need not rely on invasive hardware to achieve clinically meaningful outcomes. By targeting the vagus nerve non-invasively, the company bridges the gap between pharmaceutical intervention and implantable neurostimulation, opening the door to accessible, scalable neurotech therapies. Their work has helped validate a growing body of science around the vagus nerve as a therapeutic target for both neurological and systemic inflammatory conditions. As the neurotech industry continues to expand beyond brain-computer interfaces into autonomic and peripheral nervous system applications, electroCore's clinical and commercial progress offers a meaningful benchmark for non-invasive bioelectronic approaches.